RET and non-small cell lung carcinoma: The 1-year DoR and PFS rates were 74.1% and 68.9%, respectively, comparable to selpercatinib’s 1-year DoR and PFS rates of 66.1% and 70.6% for treatment-naïve patients, and 73.1% and 70.5% for previously treated patients.28 Overall, SY-5007 exhibits sustained clinical benefits and effective long-term disease control in patients with RET-fusion positive NSCLC, although further extended follow-up is warranted to confirm these findings.